Your browser doesn't support javascript.
loading
Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?
Mallet, Jasmina; Ramoz, Nicolas; Le Strat, Yann; Gorwood, Philip; Dubertret, Caroline.
Afiliação
  • Mallet J; Department of Psychiatry, University Hospital Louis-Mourier, Assistance Publique-Hôpitaux de Paris (AP-HP), 178 rue des Renouillers, Colombes, France. Jasmina.mallet@aphp.fr.
  • Ramoz N; Faculty of Medicine, University Paris 7 Denis Diderot, Paris, France. Jasmina.mallet@aphp.fr.
  • Le Strat Y; INSERM U894, Center of Psychiatry and Neuroscience, 102-108 Rue de la Santé, 75014, Paris, France. Jasmina.mallet@aphp.fr.
  • Gorwood P; INSERM U894, Center of Psychiatry and Neuroscience, 102-108 Rue de la Santé, 75014, Paris, France.
  • Dubertret C; University Paris 5 René Descartes, PRES Sorbonne Paris cité, Paris, France.
Eur Arch Psychiatry Clin Neurosci ; 267(7): 629-638, 2017 Oct.
Article em En | MEDLINE | ID: mdl-28190094
ABSTRACT
Cannabis use is associated with an increased risk of schizophrenia, and is considered to impact late neurodevelopment. Neurological soft signs (NSS) associated with schizophrenia are considered as markers of early neurodevelopmental impairment. Our study examines the association between heavy cannabis use before the onset of psychosis and clinical, neuropsychological and neurological symptoms, including NSS. In a cross-sectional study, we consecutively included 61 patients with schizophrenia (34 reporting heavy cannabis use before the onset of psychosis and 27 not reporting such use), in the setting of a University Hospital and a Medical Center. Symptoms assessment and substance use disorder were evaluated with the Diagnostic Interview for Genetic Studies. NSS were assessed with the Neurological Evaluation Scale. Psychopathology was assessed with the Positive and Negative Symptom Scale. All patients underwent a battery of neurocognitive tests evaluating attention, memory and executive functions domains. Patients with heavy cannabis use before the onset of psychosis showed significantly less NSS (p < 0.05), less negative symptoms (p < 10-3) and a better cognitive functioning in different domains [median reaction time (p = 0.03), episodic memory (p = 0.04), visuoconstructive praxs (p = 0.03) than their non-heavy user counterparts]. Confounding effects of alcohol and tobacco were taken into account. Age and gender were not statistically different between the two groups (p = 0.70 and p = 0.16, respectively). Our study supports the clinical, neuropsychological and neurological specificity associated with the heavy use of cannabis before the onset of schizophrenia. Patients with heavy cannabis use before the onset of schizophrenia may exhibit later neurodevelopmental impairment than those who do not report such use. Schizophrenia associated with heavy cannabis use could represent a specific phenotype.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Psicologia do Esquizofrênico / Abuso de Maconha / Transtornos Cognitivos Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Psicologia do Esquizofrênico / Abuso de Maconha / Transtornos Cognitivos Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article